Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Theranos' Holmes, Balwani Slammed By SEC For 'Massive Fraud'

Executive Summary

In another blow from the US government, securities regulators have severely penalized Theranos and its cofounder, Elizabeth Holmes, for allegedly lying to investors to raise funds.

You may also be interested in...



Babson Diagnostics Plans To Deliver What Theranos Could Not

Babson recently raised $31m to accelerate commercialization of its blood testing “ecosystem,” developed with help from Siemens Healthineers and Becton Dickinson.

Theranos Faces Two Potential Class Action Suits

Two consumers have filed attempted class action suits against Theranos that claim the lab-testing company's advertising misled consumers as to the safety and reliability of its products. The company denies the allegations. Theranos is facing exclusion from CMS over repeated lab problems.

Theranos' Correction Plan For Lab Not Enough To Stop CMS Threat

Beleaguered laboratory firm Theranos Inc. said late last month that it submitted a correction plan to the Center for Medicare and Medicaid Services to remedy the uncorrected testing deficiencies cited from an inspection by the Medicare agency. But the firm's actions so far have not been enough to stop CMS from proposing sanctions on the company in a March 18 letter, including the potential of barring its California location from operating as a clinical laboratory.

Related Content

Topics

UsernamePublicRestriction

Register

MT122347

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel